⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 30, 2024JAMA

Psychedelic Therapy Scrutinized by FDA Advisory Committee?

View at Publisher

Ask AI

Bookmark

Share

Abstract

This Viewpoint analyzes the Psychopharmacologic Drugs Advisory Committee’s decisions regarding 3,4-methylenedioxymethamphetamine–assisted therapy and what they mean for psychedelic research.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mason Marks (2024) studied this question.

synapsesocial.com/papers/6ab23f4e67821f04f678616a https://doi.org/10.1001/jama.2024.13370

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Improving the Use of FDA Advisory CommitteesOriginal Research · 2022 · 10 citations
2MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 studyRCT · 2021 · 993 citations
3MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trialRCT · 2023 · 443 citations
4How Should the FDA Evaluate Psychedelic Medicine?Human Clinical Trial · 2023 · 13 citations
5JamaJAMA · Tue,

More from JAMA

Therapy for Adults With Complicated Urinary Tract InfectionMon,
Testing for Alzheimer Disease in Asymptomatic AdultsMon,
Accessibility of Publicly Posted Kidney Transplant Waitlist Criteria Under IOTAMon,
Oxygen vs Air at Birth for Moderate- to Late-Preterm InfantsWed,
Hearing Aids for Mild to Moderate Hearing Loss in AdultsMon,